Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 09:00 ET | Source: Rimidi

Brevard Health Alliance Improves Hypertension Control with RPM Program Utilizing Rimidi's Platform and Connected Devices

Atlanta, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Rimidi, a market-leading digital health company that supports healthcare providers with EHR-integrated software, services, and connected devices, recently...
December 02, 2025 04:00 ET | Source: AKAMPION

tiakis Biotech Successfully Completes Data Package to Advance Tiprelestat into Phase II clinical trial in PAH

6-month GLP-tox study reinforces favorable safety profile of Tiprelestat Phase II Study in Pulmonary Arterial Hypertension (PAH) to be initiated by Stanford University in mid-2026 Kiel, GERMANY,...
November 06, 2025 10:23 ET | Source: Research and Markets

Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players

Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering....
November 04, 2025 11:22 ET | Source: Research and Markets

AI-Powered Acute Stroke Triage Research Report 2025: Market to Reach $3.83 Billion by 2029 at a CAGR of 22.2%, Amid Push for Faster, Smarter Emergency Care - Global Long-term Forecast to 2034

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI)-Powered Acute Stroke Triage Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The artificial...
October 30, 2025 09:15 ET | Source: Recor Medical

Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 months with Recor Medical’s Paradise Ultrasound Renal Denervation System

Palo Alto, CA, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced results from two...
October 24, 2025 11:51 ET | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals Announces FDA Approval of JAVADIN™ (clonidine hydrochloride) Oral Solution

Woburn, MA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Javadin™ (clonidine hydrochloride) oral...
October 23, 2025 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)

Company launches multi-channel promotional campaign to drive market adoption U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the...
October 10, 2025 04:43 ET | Source: Research and Markets

Asia-Pacific Next-Generation Intervention Cardiology Forecast Report 2025: Market to Reach $13.05 Billion by 2035, Driven by AI and Robotics Lead Precision

Dublin, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Next-Generation Intervention Cardiology Market: Focus on Product Type, Indication Type, End User, and Country - Analysis and Forecast,...
October 02, 2025 07:00 ET | Source: George Medicines

George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil

Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single...
September 16, 2025 08:05 ET | Source: Scienture Holdings, Inc.

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK,...